The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.

Provided herein are methods of uses of a P-selectin inhibitor alone or in combination with a Von Willebrand factor (VWF) inhibitor. The methods include the administration of a P-selectin inhibitor alone or in combination with a Von Willebrand factor (VWF) inhibitor for the treatment of COVID-19 associated endothelial injury and/or reducing the risk of thrombosis in a subject of need thereof.

The invention relates to the field of diagnostic immunology. Provided are means and methods for multiparameter cytometry-based leukocyte subsetting, which is advantageously used for the monitoring of the immune status of a subject, and/or for monitoring the effects of an immune modulatory treatment. Provided among others is a reagent composition comprising antibodies conjugated to a detectable label, the conjugated antibodies being directed against the following combination of markers: CD141, HLA-DR, CD16, CD33, CD300e, CD303 and CD14, wherein the antibodies directed against CD300e and CD303 may be conjugated to the same label.

The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations.

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

The invention relates to a method of treating chronic kidney disease due to sickle cell nephropathy in a patient in need of such treatment, comprising administering a pharmaceutically effective amount of an anti-P-selectin antibody or a binding fragment thereof to said patient and related invention embodiments (uses, methods, pharmaceutical preparations and use in the preparation of pharmaceutical preparations).

Methods for treating, preventing and reducing the progression of neurodegenerative and neurological diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention inhibit one or both of TIM-1 and P-selectin function and reduce leukocyte and platelet cell adhesion, activation and interaction with the vascular endothelium and infiltration of leukocytes into the brain.

The present invention provides peptides useful as epitope tags, which may be fused to a polypeptide of interest, as well as antibodies that specifically bind to these peptides. The peptides and/or antibodies can be used for detecting, immobilizing, isolating or purifying a molecule that is conjugated to such a peptide and/or antibody.

The invention relates to a method of treating priapism in a patient in need of such treatment, comprising administering a pharmaceutically effective amount of an anti-P-selectin antibody or a binding fragment thereof to said patient, especially wherein the patient is suffering from Sickle Cell Disease (SCD), and related invention embodiments (uses, methods, pharmaceutical preparations and use in the preparation of pharmaceutical preparations).

The present invention describes compositions and methods for targeting complement inhibition to sites of p-selectin expression, and compositions for inhibiting p-selectin and complement.